Drug Trial Radar · NCT07086976
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Aug 18, 2025
Primary completion
May 31, 2028
Study completion Dec 26, 2029
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jul 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb response (DHR) compared with placebo in approximately 90 male and female participants ≥ 18 years of age with a confirmed diagnosis of primary wAIHA. Following a 4-week screening period, eligible participants will be randomized in a 2:1 ratio to receive rilzabrutinib or placebo in primary analysis period (PAP) for a duration of up to 24 weeks. All participants who completed PAP will then continue in open-label period (OLP) to receive rilzabrutinib for a duration of 28 weeks. Upon the completion of OLP, only participants who demonstrate Hb increase during the last 8 weeks of OLP per specified criteria in the protocol will be eligible to continue in long-term extension (LTE) of the study. The duration of the LTE period will be from the first-participant-in (FPI)-LTE until the last participant completes 52 weeks in LTE. The safety follow-up period of this study following treatment completion or discontinuation will be 2 weeks.
Conditions
- Autoimmune Haemolytic Anaemia
Interventions
rilzabrutinibDrug
Pharmaceutical form:tablet-Route of administration:oral
placeboDrug
Pharmaceutical form:tablet-Route of administration:oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving DHR. DHR is defined as an increase of Hb by ≥2 g/dL from baseline on at least two thirds of evaluable scheduled visits between Week 12 and Week 24 (inclusive) in the PAPTime frame: By Week 24
Locations
105 sites in 18 countries. Site status is shown where the registry gives one.
Mayo Clinic in Arizona - Phoenix- Site Number : 8400032
Phoenix, Arizona · Recruiting
Noble Clinical Research- Site Number : 8400003
Tucson, Arizona · Completed
City of Hope Comprehensive Cancer Center- Site Number : 8400023
Duarte, California · Recruiting
Cancer and Blood Specialty Clinic - Los Alamitos- Site Number : 8400038
Los Alamitos, California · Recruiting
USC Norris Comprehensive Cancer Center- Site Number : 8400007
Los Angeles, California · Recruiting
Stanford University Medical Center- Site Number : 8400026
Stanford, California · Recruiting
Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center- Site Number : 8400006
Torrance, California · Recruiting
Yale University School of Medicine- Site Number : 8400027
New Haven, Connecticut · Recruiting
MedStar Georgetown University Hospital- Site Number : 8400004
Washington D.C., District of Columbia · Recruiting
Hialeah Hospital- Site Number : 8400009
Hialeah, Florida · Recruiting
Sylvester Comprehensive Cancer Center- Site Number : 8400031
Miami, Florida · Recruiting
University Hospital and Medical Center- Site Number : 8400005
Tamarac, Florida · Recruiting
Tulane University School of Medicine- Site Number : 8400037
New Orleans, Louisiana · Recruiting
Massachusetts General Hospital- Site Number : 8400001
Boston, Massachusetts · Recruiting
Beth Israel Deaconess Medical Center - Boston- Site Number : 8400034
Boston, Massachusetts · Recruiting
University of Michigan Health System - Ann Arbor- Site Number : 8400014
Ann Arbor, Michigan · Recruiting
Henry Ford Hospital- Site Number : 8400012
Detroit, Michigan · Recruiting
Mayo Clinic in Rochester - Minnesota- Site Number : 8400008
Rochester, Minnesota · Recruiting
Montefiore Medical Center - Einstein Campus- Site Number : 8400011
The Bronx, New York · Recruiting
Cleveland Clinic - Cleveland- Site Number : 8400029
Cleveland, Ohio · Recruiting
Ohio State University Hospital East- Site Number : 8400020
Columbus, Ohio · Recruiting
Fox Chase Cancer Center - Philadelphia- Site Number : 8400019
Philadelphia, Pennsylvania · Recruiting
Brown University Health - Rhode Island Hospital- Site Number : 8400028
Providence, Rhode Island · Recruiting
Baptist Memorial Hospital- Site Number : 8400018
Memphis, Tennessee · Recruiting
UT Health - San Antonio- Site Number : 8400015
San Antonio, Texas · Recruiting
Fred Hutchinson Cancer Center- Site Number : 8400016
Seattle, Washington · Recruiting
Gundersen Health System - La Crosse Medical Center- Site Number : 8400033
La Crosse, Wisconsin · Recruiting
Investigational Site Number : 0320003
Buenos Aires, Argentina · Recruiting
Investigational Site Number : 0320002
Buenos Aires, Argentina · Recruiting
Investigational Site Number : 0320001
Rosario, Santa Fe Province, Argentina · Recruiting
Investigational Site Number : 0400001
Vienna, Austria · Recruiting
Investigational Site Number : 0400002
Vienna, Austria · Recruiting
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760003
São Paulo, Brazil · Recruiting
Hemoes - Centro Estadual de Hemoterapia e Hematologia Marcos Daniel Santos- Site Number : 0760002
Vitória, Espírito Santo, Brazil · Recruiting
Universidade Federal de Goias- Site Number : 0760001
Goiânia, Goiás, Brazil · Recruiting
Investigational Site Number : 1560001
Beijing, China · Recruiting
Investigational Site Number : 1560007
Chengde, China · Recruiting
Investigational Site Number : 1560011
Guangzhou, China · Recruiting
Investigational Site Number : 1560005
Guangzhou, China · Recruiting
Investigational Site Number : 1560009
Hohhot, China · Recruiting
Showing 40 of 105 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.